Journal profile · ONCOLOGY
BREAST CANCER RESEARCH
ISSN 1465-542X · BioMed Central · ENGLAND · Founded 1999
BREAST CANCER RESEARCH: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.2; fully open access; APC about USD 4,190; median 143 days to acceptance (110 articles, last 24 months); community-reported acceptance: fairly easy; 249 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
BREAST CANCER RESEARCH is published by BioMed Central and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Cancer Cells and Metastasis and Breast Lesions and Carcinomas, together about 30.7% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Lewis ChodoshPublisher website
Editorial board by country: none in mainland China; most named United States 103, United Kingdom 18, Australia 7, France 5, Netherlands 4 (155 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology15.8%
- Cancer Cells and MetastasisMedicine8%
- Breast Lesions and CarcinomasMedicine7%
- HER2/EGFR in Cancer ResearchMedicine6.8%
- Cancer Risks and FactorsMedicine6.5%
- Estrogen and related hormone effectsBiochemistry, Genetics and Molecular Biology6.4%
- BRCA gene mutations in cancerBiochemistry, Genetics and Molecular Biology6.2%
- Global Cancer Incidence and ScreeningMedicine5.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCAB AbstractsPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.2LetPub ·
- Impact factor (publisher) 2025
- 6.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 7.3Publisher website ·
- CiteScore 2026-06
- 8.1LetPub ·
- SJR 2026-06
- 1.91LetPub ·
- SNIP 2026-06
- 1.45LetPub ·
- h-index
- 126LetPub ·
- h-index
- 211OpenAlex ·
- i10-index
- 3,143OpenAlex ·
- 2-year mean citedness
- 5.66OpenAlex ·
- Self-citation rate
- 3.2%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 236LetPub ·
- Downloads per year (publisher) 2025
- 4,500,000Publisher website ·
Articles by year OpenAlex count · 5,937 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 192 | 192 | 61 |
| 2025 | 249 | 249 | 1,140 |
| 2024 | 193 | 193 | 2,390 |
| 2023 | 155 | 155 | 3,122 |
| 2022 | 101 | 101 | 2,750 |
| 2021 | 120 | 120 | 4,356 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
143 daysMedian, submission to acceptance · P25–P75 99 days – 193 days
- Acceptance to online
- median 20 days (110 articles)
- Submission to online
- median 168 days
- Sample
- 110 articles with submission and acceptance dates (491 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 13 daysPublisher website ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,390 / USD 4,190 / GBP 2,990 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 4,190 / EUR 3,390 / GBP 2,990 | — | — | |
| LetPub | GBP 2,890 / USD 3,990 / EUR 3,290 | Yes | — | |
| Publisher website | GBP 2,990 / USD 4,190 / EUR 3,390 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted7
- brief reportResearch articles Correspondence Reviews Brief report Perspective Meeting reports Matters ArisingLength not stated
- correspondenceResearch articles Correspondence Reviews Brief report Perspective Meeting reports Matters ArisingLength not stated
- matters arisingResearch articles Correspondence Reviews Brief report Perspective Meeting reports Matters ArisingLength not stated
- meeting reportsResearch articles Correspondence Reviews Brief report Perspective Meeting reports Matters ArisingLength not stated
- perspectiveResearch articles Correspondence Reviews Brief report Perspective Meeting reports Matters ArisingLength not stated
- research articlesResearch articles Correspondence Reviews Brief report Perspective Meeting reports Matters ArisingLength not stated
- reviewsResearch articles Correspondence Reviews Brief report Perspective Meeting reports Matters ArisingLength not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, License & copyright, Open access, Peer review
- Authorship
Manuscripts must be submitted by an author, not a third party. Model summary
Please note that a manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party.
Source ↗Publisher website ·- Data availability Formatting the 'Availability of data and materials' section of your manuscript
Data sharing strongly encouraged or required; deposit in public repositories where appropriate. Model summary
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Open access articles published under CC BY-NC-ND or CC BY licences. Model summary
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Breast Cancer Research articles are published open access under a CC BY-NC-ND (Creative Commons Attribution …
Source ↗Publisher website ·- Open access Benefits of open access
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Founded
- 1999
- ISSN
- 1465-542X
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about BREAST CANCER RESEARCH
What CAS zone is BREAST CANCER RESEARCH in?
In the 2025 upgraded edition of the CAS Journal Ranking, BREAST CANCER RESEARCH is in Zone 2 of Medicine, and in Zone 2 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of BREAST CANCER RESEARCH?
The latest impact factor listed by LetPub is 6.2; CiteScore 8.1, h-index 211.
How long does peer review take at BREAST CANCER RESEARCH?
Based on the dates recorded on 110 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 143 days (interquartile range 99–193 days); authors report an average review time of 3–8 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of BREAST CANCER RESEARCH based?
Of the 155 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (103), United Kingdom (18) and Australia (7). Counted from the institutions listed on the board page; for reference only.
Which databases index BREAST CANCER RESEARCH?
According to LetPub and DOAJ records, BREAST CANCER RESEARCH is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase, CAS and CAB Abstracts; that list has not been checked against each database.
Is BREAST CANCER RESEARCH open access, and what is the APC?
BREAST CANCER RESEARCH is a fully open-access journal. APC about USD 4,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .